Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo

Journal of Pediatric Surgery

Volumn 38, Issue 3, 2003, Pages 301-307

  Redlinger Jr , Richard E ^a   Mailliard, Robbie B ^a   Lotze, Michael T ^a   Barksdale Jr , Edward M ^a   Ziegler, M ^b   Gittes, G ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b Department of Pediatric Surgery ^*

Author keywords

Dendritic cells; Immunotherapy; Interleukin 18; Interleukin 2; Neuroblastoma

Indexed keywords

RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; DEATH; DENDRITIC CELL; DRUG POTENTIATION; IMMUNITY; MALE; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VACCINATION;

EID: 0037370285     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2003.50098     Document Type: Conference Paper

References (29)

1. Morgan DA, Ruscetti FW. Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008, 1976
2. Bukowski RM, McLain D. Olencki T, et al: Interleukin-2: Use in solid tumors. Stem Cells 11:26-32, 1993
3. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
4. Gaffen SL. Goldsmith MA, Green WC: Interleukin-2 and interleukin-2 receptor, in Thomson A (ed): The Cytokine Handbook (ed 3). San Diego, CA, Academic Press, 1998. pp 73-103
5. Alvarado CS, Findley HW, Chan WC, et al: Natural killer cells in children with malignant solid tumors. Cancer 63:83-89, 1989
6. Squire R, Fowler CL, Brooks SP, et al: The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma. J Pediatr Surg 25:381-386, 1990
7. Pession A, Prete A, Locatelli F, et al: Immunotherapy with low-dose recombinant IL-2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 78:528-533, 1998
8. Toren A, Nagler A, Rozenfeld-Granot G, et al: Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation 70:1100-1104, 2000
9. Lotze MT, Chang AE, Seipp XA, et al: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256:3117-3124, 1986
10. Valteau-Couanet D, Rubie H, Meresse V, et al: Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 16:515-520, 1995
11. Nakamura K, Okamura H, Wada M, et al: Endotoxin-induced serum factor that stimulates y interferon production. Infect Immun 57:590-595, 1989
12. Tsutsui H, Matsui K, Kawada N, et al: IL-18 accounts for both TNF-a and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 159:3961-3967, 1997
13. Matikainen S, Paananen A, Miettinen M, et al: IFN-α and IL-18 synergistically enhance IFN-γ production in human NK cells: Differential regulation of Stat4 activation and IFN-γ gene expression by IFN-α and IL-12. Eur J Immunol 31:2236-2245, 2001
14. Osaka T, Peron JM, Cai Q, et al: Interferon-γ-inducing factor/ IL-18 administration mediates IFN-γ and IL- 12-independent antitumor effects. J Immunol 160:1742-1749, 1998
15. Son YI, Dallal RM, Mailliard RB, et al: Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-y production and expansion of natural killer cells. Can Res 61:884-888, 2001
16. Son YI, Egawa S, Tatsumi T, et al: A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J lmmunol Methods 262:145-157, 2002
17. Redlinger RE, Shimizu T, Remy T, et al: Cellular mechanisms of IL-12 mediated neuroblastoma regression. Presented at the American Academy of Pediatrics, 2001 National Conference and Exhibition, San Francisco, CA, October 20-21, 2001. J Pediatr Surg 38:199-204, 2003
18. Gottlieb DJ, Brenner MK, Heslop HE. et al: A phase I clinical trial of recombinant interleukin-2 following high-dose chemoradiotherapy for hematological malignancy: Applicability to the elimination of minimal residual disease. Br J Cancer 60:610-615, 1989
19. Toren A, Ackerstein A, Slavin S, et al: Role of interleukin-2 in human hematological malignancies. Med Oncol 12:177-186, 1995
20. Pardo N, Marti F, Fraga G, et al: High-dose systemic Interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: Pilot study. Med and Ped Oncol 27:534-539, 1996
21. Cooper MJ, Hutchins GM, Mennie RJ, et al: Beta 2-Microglobulin expression in human embryonal neuroblastoma cells reflects its developmental regulation. Cancer Res 50:3694-3700, 1990
22. Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opinion Immunol 7:704-710, 1995
23. Tomura M, Zhou XY, Maruo S, et al: A critical role for IL-18 in the proliferation and activation of NK1.1 + CD3- cells. J Immunol 160:4738-4746, 1998
24. Kubota A, Lian RH, Lohwasser S, et al: IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules. J Immunol 163:6488-6493, 1999
25. Shimizu T, Berhanu A. Redlinger RE, et al: Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 36:1285-1292, 2001
26. Steinman RM: The dendritic system and its role in immunogenicity. Ann Rev Immunol 9:271-296, 1991
27. Fernandez NC, Lozier A, Flamaent C, et al: Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Medicine 5:405-411, 1999
28. Palucka K, Banchereau J: Dendritic Cells: A link between innate and adaptive immunity. J Clinical Immunol 19:12-23, 1999
29. Gerosa F, Baldani-Guerra B, Nisii C, et al: Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195:327-333, 2002